603259 药明康德
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入17,240,918-8.64%40,340,80739,354,77822,902,38516,535,431
减:营业总成本12,203,655-7.23%28,708,59129,800,81118,574,51613,928,304
    其中:营业成本10,453,937-6.87%23,728,80024,677,21714,592,25610,253,276
               财务费用(603,224)25.53%(338,119)(247,968)84,082519,804
               资产减值损失11,413-120.41%(156,509)(175,951)(33,056)(62,642)
公允价值变动收益(99,588)-132.02%(37,809)770,079(93,387)52,271
投资收益22,379-93.01%233,849187,9491,356,269606,231
    其中:对联营企业和合营企业的投资收益111,649-262.33%(67,560)(46,271)(117,290)(90,752)
营业利润5,078,454-20.80%11,872,28610,652,2496,037,7253,389,485
利润总额5,049,554-21.04%11,831,99110,618,4766,015,6093,369,376
减:所得税费用768,708-25.97%2,131,7311,715,866879,662383,126
净利润4,280,846-20.09%9,700,2608,902,6115,135,9472,986,250
减:非控股权益41,024-6.29%93,51188,89838,79226,015
股东净利润4,239,822-20.20%9,606,7498,813,7135,097,1552,960,235

市场价值指针
每股收益 (元) *1.460-19.34%3.2703.0101.7501.060
每股派息 (元) *----0.9900.8930.5170.363
每股净资产 (元) *18.79011.93%18.57015.73713.02013.308
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容